Unfortunately, in cancer, the overexpression of PD-L1 has often been associated with immunoevasion and a poor prognosis for patients; while little is known about the role that CMTM6 found in novel non-canonical subcellular locations might play in cancer, the presence of this molecule in some cancers such as colorectal, melanoma, breast, lung, and pancreas has (most notably in pancreatic adenocarcinomas) been associated with shorter overall survival and enhanced prognostic value of PD-L1 expression, suggesting a cooperative effect between these two molecules in disease progression [20]. Here, CD274 is linked to melanoma.